Powder: -20°C for 3 years | In solvent: -80°C for 1 year
AS1810722, a fused bicyclic pyrimidine derivative, is an orally active and potent inhibitor of STAT6, demonstrating an IC50 of 1.9 nM. It exhibits effective inhibition of CYP3A4, positioning it as a promising candidate for research into allergic diseases, including asthma and atopic conditions.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
1 mg | 在庫あり | ¥ 26,500 | |||
5 mg | 在庫あり | ¥ 57,000 | |||
10 mg | 在庫あり | ¥ 91,500 | |||
25 mg | 在庫あり | ¥ 152,500 | |||
50 mg | 在庫あり | ¥ 217,000 | |||
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 59,500 |
説明 | AS1810722, a fused bicyclic pyrimidine derivative, is an orally active and potent inhibitor of STAT6, demonstrating an IC50 of 1.9 nM. It exhibits effective inhibition of CYP3A4, positioning it as a promising candidate for research into allergic diseases, including asthma and atopic conditions. |
ターゲット&IC50 | STAT6:1.9 nM |
In vitro | AS1810722 showed potent STAT6 inhibition and a good CYP3A4 inhibition profile.?AS1810722 also inhibited in vitro Th2 differentiation without affecting type 1 helper T (Th1) cell differentiation and eosinophil infiltration in an antigen-induced mouse asthmatic model after oral administration. |
分子量 | 477.51 |
分子式 | C25H25F2N7O |
CAS No. | 909561-15-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 62.5 mg/mL (130.89 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
AS1810722 909561-15-5 JAK/STAT signaling Metabolism Stem Cells P450 STAT inhibit CYPs AS-1810722 Cytochrome P450 eosinophil allergic orally AS 1810722 Inhibitor asthma IL-4 infiltration IFN-γ inhibitor